Why This Obesity Drugmaker's Prescription Data Tells Only Half the Story

As biotech investors continue to wait for Arena Pharmaceuticals to launch its obesity drug Belviq, pharmaceutical company Vivus (NASDAQ: VVUS  ) has been trying to ramp up sales for its rival drug Qsymia. The company's slow drug launch has been the topic of much debate in past quarters, but it recently reported that its total number of prescriptions shipped in March were 42% greater than scripts in January. Should investors be excited about this result, or will the real catalyst for this stock be its upcoming earnings report for the first quarter of 2013? Health-care analyst Max Macaluso sheds light on this topic in the following video.

Is now the time to sell VIVUS?
VIVUS' shares were clobbered after Qsymia's dismal launch. Investors everywhere are wondering whether the tide will turn for this fledgling drugmaker or if now is the perfect time to sell. In a new premium research report, the Fool's top health-care contributor breaks down this complex story and explains the details VIVUS investors must know -- including reasons to buy and sell. To find out more about this premium report click here now.

Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 22, 2013, at 8:55 PM, gazoo99 wrote:

    Lest we forget........

    VVUS previously spent 58 mil to get 2 mil in sales!

    What is the cost of sales here? Sure there's an increasein scripts.... but at what cost?

    That was not posted....... wonder why?

  • Report this Comment On April 23, 2013, at 9:56 AM, adumfraudstain wrote:

    The time to sell VVUS was last year in $20's when stock spiked above $22 at adcom and later to $31 at FDA approval leaving huge gap from $10's open- we recommended doing just that.

    Qsymia nothing more than reformulated generic drugs already on market several decades while US obesiity rates tripled. And wall street loves Qsymia because they understand that the status quo profit stream with existing obesity rates remains intact. Lol!

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2378162, ~/Articles/ArticleHandler.aspx, 9/29/2016 7:52:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
VVUS $1.17 Down -0.03 -2.50%
VIVUS CAPS Rating: **